Publicacións en colaboración con investigadores/as de Hospital Clinic Barcelona (20)

2024

  1. Real-life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir

    Alimentary Pharmacology and Therapeutics, Vol. 60, Núm. 2, pp. 201-211

2023

  1. Increasing and sustaining blood-borne virus screening in Spain and Portugal throughout the COVID-19 pandemic: a multi-center quality improvement intervention

    Frontiers in public health, Vol. 11, pp. 1268888

2021

  1. Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy-proven nonalcoholic fatty liver disease subjects

    Liver International, Vol. 41, Núm. 9, pp. 2076-2086

2020

  1. Development and Validation of Hepamet Fibrosis Scoring System–A Simple, Noninvasive Test to Identify Patients With Nonalcoholic Fatty Liver Disease With Advanced Fibrosis

    Clinical Gastroenterology and Hepatology, Vol. 18, Núm. 1, pp. 216-225.e5

  2. Significant fibrosis predicts new-onset diabetes mellitus and arterial hypertension in patients with NASH

    Journal of Hepatology, Vol. 73, Núm. 1, pp. 17-25

2017

  1. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection

    Journal of Viral Hepatitis, Vol. 24, Núm. 3, pp. 226-237

  2. Effectiveness and safety of sofosbuvir-based regimens plus an NS5A inhibitor for patients with HCV genotype 3 infection and cirrhosis. Results of a multicenter real-life cohort

    Journal of Viral Hepatitis, Vol. 24, Núm. 4, pp. 304-311

2010

  1. Tratamiento del carcinoma hepatocelular en España. Análisis de 705 casos en 62 centros

    Medicina Clinica, Vol. 134, Núm. 13, pp. 569-576

2008

  1. Haemodynamic Assessment of Portal Hypertension

    Textbook of Hepatology: From Basic Science to Clinical Practice, Third Edition (Blackwell Publishing Ltd), pp. 658-665

  2. Portal Hypertension-Related Complications After Acute Portal Vein Thrombosis: Impact of Early Anticoagulation

    Clinical Gastroenterology and Hepatology, Vol. 6, Núm. 12, pp. 1412-1417

2007

  1. Influencia de los polimorfismos genéticos en la respuesta terapéutica a los bloqueadores beta

    Gastroenterologia y Hepatologia Continuada

2006

  1. Ascorbic acid improves the intrahepatic endothelial dysfunction of patients with cirrhosis and portal hypertension

    Hepatology, Vol. 43, Núm. 3, pp. 485-491

  2. Influence of beta-2 adrenergic receptor gene polymorphism on the hemodynamic response to propranolol in patients with cirrhosis

    Hepatology, Vol. 43, Núm. 1, pp. 34-41

  3. Pharmacological Reduction of Portal Pressure and Long-Term Risk of First Variceal Bleeding in Patients with Cirrhosis

    American Journal of Gastroenterology, Vol. 101, Núm. 3, pp. 506-512

  4. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome

    Hepatology, Vol. 43, Núm. 1, pp. 27-33

2005

  1. Impact of prior portosystemic shunt procedures on outcome of liver transplantation

    Surgery, Vol. 137, Núm. 6, pp. 620-625

  2. Utility of color doppler ultrasonography predicting TIPS dysfunction

    American Journal of Gastroenterology, Vol. 100, Núm. 12, pp. 2696-2701

2004

  1. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome

    Hepatology, Vol. 40, Núm. 5, pp. 1197-1202

  2. Simvastatin Enhances Hepatic Nitric Oxide Production and Decreases the Hepatic Vascular Tone in Patients with Cirrhosis

    Gastroenterology, Vol. 126, Núm. 3, pp. 749-755

2003

  1. Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis

    Hepatology, Vol. 37, Núm. 4, pp. 902-908